Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children710.24287/1726-1708-2017-16-4-43-50СтатьиTumors of Ewing family: treatment results of pediatric patients in Belarus RepublicОпухоли семейства Юинга: результаты лечения пациентов детского возраста в Республике Беларусьhttps://orcid.org/0000-0003-2071-8143KisialeuL. P.КиселёвЛ.П.
Belarus

M.D., Ph.D., сhief of the Department of Oncology and Hematology for Older Children

223053, Belarus, Minsk Region, v. Borovliany, Frunzenskaya, 43.

Tel.: +375 296 637833Fax: +375 172 654222

leonslight@mail.ruRepublican Research Center for Pediatric Oncology, Hematology and Immunology, MinskРеспубликанский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики Беларусь09112017164435009082018Copyright ©; 2017, «D. Rogachev NMRCPHOI»Copyright ©; 2017, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2017«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/7

Tumors of Ewing family (previously – Peripheral primitive neuroectodermal tumor) (TEF) arise in any bone or soft tissue and differs from the classical Ewing's sarcoma (ES) by markers of neuronal differentiation. The aim of the study was to investigate whether patient characteristics differ between cases with favorable and unfavorable outcomes. We also studied whether treatment strategies (for rhabdoid tumor or for classical ES) affects the clinical outcome of patients with TEF. 53 pediatric patients included in the Belarus Republic (RB) cancer registry database (involved in International Agency for Research on Cancer (IARC)) from 1999 to 2014 were evaluated. Survival rate was estimated via the Kaplan-Meier method and compared using logrank tests and Cox proportional hazard models. 15-year event-free survival (EFS) of all patients was 50.4%, for the cohorts of patients with localized and metastatic disease OS was 57.9 and 20.0% respectively. Known clinical characteristics (age, sex, tumors volume and other) did not differ between patients with localized TEF depending on the availability of favorable or unfavorable outcomes. Use of protocols for rhabdomyosarcoma associated with worse overall survival results (65% vs. 50%, n.s.) for localized TEF. Treatment results for patients with TEF of the Belarus Republic comply with generally accepted standards. Patients with metastatic status need new treatment strategies. Searching for new predictive markers is necessary for early detection of resistant to conventional treatment patients with localized TEF. For patients with localized TEF, who treated according to classical ES protocols, established an increasing number of favorable outcomes compared to curating according to the rhabdomyosarcomas chemotherapy schemes.

childrentumors of Ewing familysurvivaltreatmentдетивыживаемостьлечениеопухоли семейства Юинга костей и мягких тканейПетрович С.В., Алейникова О.В. Особенности заболеваемости злокачественными новообразованиями детей первого года жизни в Республике Беларусь. Медико-биологические аспекты аварии на Чернобыльской АЭС, 2004; 1: 3-11.Петрович С.В., Алейникова О.В. Особенности заболеваемости злокачественными новообразованиями детей первого года жизни в Республике Беларусь. Медико-биологические аспекты аварии на Чернобыльской АЭС, 2004; 1: 3-11.Румянцев А.Г., Варфоломеева С.Р., Грачев Н.С., Карачунский А.И., Новичкова Г.А. Принципы и инструменты доказательной медицины в детской гематологии/онкологии. Доктор.Ру, 2015; 10 (111): 6-13.Delattre O., Zucman J., Melot T. The Ewing family of tumors: A subgroup of small-roundcell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331: 294-9.De Gruttola V.G., Clax P., Demets D.L., Downing G.J., Ellenberg S.S., Friedman L., et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. Control. Clin Trials 2001; 22: 485-502.Smith M.A., Altekruse S.F., Adamson P.C., Reaman G.H., Seibel N.L. Declining childhood and adolescent cancer mortality. Cancer 2014; 120: 2497-506.Applebaum M.A., Worch J., Matthay K.K., Goldsby R., Neuhaus J., West D.C., Dubois S.G., et al. Clinical features and outcomes in patients with extraskeletal Ewing sarcoma. Cancer 2011; 117 (13): 3027-32.Grier H.E., Krailo M.D., Tarbell N.J., Link M.P., Fryer C.J.H., Pritchard D.J., et al: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348 (8): 694-701.Arndt V., Lacour B., Steliarova-Foucher E., Spix C., Znaor A., Pastore G., et al. Up-to-date monitoring of childhood cancer long-term survival in Europe: tumours of the sympathetic nervous system, retinoblastoma, renal and bone tumours, and soft tissue sarcomas. Ann Oncol 2007; 18: 1722-33.Smith M.A. The impact of doxorubicin dose intensity on survival of patients with Ewing’s sarcoma. J Clin Oncol 1991; 9: 889-91.Granowetter L., Womer R., Devidas M., Krailo M., Wang C., Bernstein M., et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group study. J Clin Oncol 2009; 27: 2536-41.Womer R.B., West D.C., Krailo M.D., Dickman P.S., Pawel B.R., Grier H.E., et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol 2012; 30 (33): 4148-54.Paulussen M., Craft A.W., Lewis I., Hackshaw A., Douglas C., Dunst J., et al. Results of the EICESS-92 Study: two randomized trials of Ewing’s sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J Clin Oncol 2008; 26: 4385-93.Juergens C., Weston C., Lewis I., Whelan J., Paulussen M., Oberlin O., et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood & Cancer 2006; 47: 22-9.КиселёвЛ.П., СавицкаяТ.В., ЛипайН.В., АлейниковаО.В. TFPI2, VEGFА165 иVEGFА189 какнезависимыефакторыпрогнозалокализованныхформсаркомыЮинга. Онкологический журнал (Минск, Республика Беларусь), 2016; 10: 93-100.Raney R.B., Anderson J.R., Barr F.G., Donaldson S.S., Pappo A.S., Qualman S.J., et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: a selective review of Intergroup Rhabdomyosarcoma Study Group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J Pediatr Hematol Oncol 2001; 23:215-20.